Skip to search formSkip to main contentSkip to account menu

temsirolimus

Known as: 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin, 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin, temsirolimus [Chemical/Ingredient] 
An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs… 
National Institutes of Health

Related topics

Related topics

10 relations
1.2 ML temsirolimus 25 MG/ML Injection [Torisel]FRAP1 protein, humanNCIt Antineoplastic Agent TerminologyNegative Regulation of G1 Phase

Narrower (2)

CCI 779Torisel

Broader (1)

Sirolimus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
FLT 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
634. 42. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and… 
2012
2012
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.
4047 Background: PNET has long had few effective therapies other than chemotherapy. Recent placebo-controlled phase III trials of… 
2010
2010
Effects of treatment by temsirolimus on patients with clear cell carcinoma of the ovary.
5086 Background: Clear cell carcinoma (CCC) of the ovary has been well known to be chemotherapy resistant. When the primary… 
2010
2010
Concurrent involved field radiation therapy and Temsirolimus in refractory mantle cell lymphoma (MCL)
Temsirolimus, an inhibitor of mammalian target of rapamycin, has antitumor activity and improves progress-free survival in… 
2010
2010
Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer…
TPS242 Background: This is an ongoing study of cixutumumab (cix) and temsirolimus (tem) in chemo-naive patients with metastatic… 
2008
2008
Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy
16067 Background: TEM is a selective inhibitor of mTOR, a regulator of cell proliferation, growth and survival, approved for… 
2008
2008
Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
5116 Background: Temsirolimus (TEMSR), an inhibitor of mTOR has been approved in the US for treatment of patients (pts) with… 
2008
2008
A phase I study of temsirolimus in combination with metformin in advanced solid tumors
AACR Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008; Monterey, CA B1 Background: Temsirolimus is an… 
2008
2008
Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus
5099 Background: Sunitinib is an oral tyrosine kinase inhibitor of VEGFR-2, PDGFR, KIT, and FLT3 and a first line standard of… 
2007
2007
mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals
C144 Background: Temsirolimus is a selective inhibitor of the mammalian target of rapamycin (mTOR), which has been approved by…